According to a recent LinkedIn post from Cleerly, the company is emphasizing the clinical distinction between calcified and non‑calcified coronary plaque and the limitations of traditional diagnostic methods in detecting higher‑risk soft plaque. The post highlights that Cleerly’s AI‑driven plaque analysis uses non‑invasive CCTA imaging to color‑code and quantify different plaque types, aiming to provide more granular cardiac risk assessment.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The post also notes that Cleerly’s technology is now associated with a new Category I CPT code and broader insurance coverage, which the company suggests extends reimbursement to a majority of insured lives in the U.S. For investors, expanded CPT recognition and coverage could support higher procedure volumes, improve adoption among cardiology practices and health systems, and potentially strengthen Cleerly’s competitive position in the cardiac imaging and AI diagnostics market.
This development, if sustained, may contribute to more predictable revenue pathways tied to reimbursed clinical use rather than solely research or pilot deployments. It also underscores growing payer and clinician interest in AI‑enabled, image‑based cardiovascular risk stratification, which could influence valuations across the wider digital health and cardiac imaging ecosystem.